The current state of pertussis vaccination in pregnancy around the world, with recommendations for improved care: Consensus statements from the Global Pertussis Initiative

COURTNEY OLSON-CHEN ; GEETA K SWAMY; BERNARD GONIK; KEVIN FORSYTH; ULRICH HEININGER; HOZBOR DANIELA; CARL HEINZ WIRSING VON KÖNIG; AMAR J CHITKARA; KARINA A TOP; RUDZANI MULOIWA; MALIKAH VAN DER SCHYFF; TINA Q TAN

International Journal of Gynecology and Obstetrics

John Wiley and Sons Ltd

Año: 2024

Abstract Bordetella pertussis, which causes a respiratory disease known as pertussis ("whooping cough") remains an important global challenge, with the incidence in pertussis cases increasing in recent years. Newborns and infants are at increased risk for severe morbidity and mortality from this bacterium. Vaccination in pregnancy has become an important strategy to both passively transfer immunity as well as prevent infection in pregnant persons, who are a major source of newborn infection, thus attempting to decrease the impact of this serious disease. It is considered safe for the pregnant person, the developing fetus, and the infant, and during the first 3 months of life it has been shown to be highly effective in preventing pertussis. There are a variety of strategies, recommendations, and adherence rates associated with pertussis vaccination in pregnancy around the world. We summarize the 2021 Global Pertussis Initiative Annual Meeting that reviewed the current global status of pertussis vaccination in pregnancy and remaining medical and scientific questions, with a focus on vaccination challenges and strategies for obstetric and gynecologic healthcare providers.